AbbVie (ABBV)
198.47
+5.13 (2.65%)
NYSE · Last Trade: May 3rd, 10:26 PM EDT
Detailed Quote
Previous Close | 193.34 |
---|---|
Open | 195.17 |
Bid | 194.91 |
Ask | 199.50 |
Day's Range | 194.63 - 198.98 |
52 Week Range | 153.58 - 218.66 |
Volume | 6,425,168 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.560 (3.31%) |
1 Month Average Volume | 9,507,904 |
Chart
About AbbVie (ABBV)
AbbVie is a global biopharmaceutical company that focuses on the research, development, and commercialization of advanced therapies to treat complex diseases across multiple therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is known for its innovative biologics and pharmaceutical products aimed at addressing unmet medical needs, improving patient outcomes, and enhancing the quality of life for individuals suffering from chronic and acute health conditions. Through a combination of scientific expertise and strategic partnerships, AbbVie continuously strives to push the boundaries of medical science and expand its portfolio of leading-edge treatments. Read More
News & Press Releases
Being prepared is important
Via The Motley Fool · May 3, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via Benzinga · May 3, 2025
The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities.
Via MarketBeat · May 2, 2025
Via Benzinga · April 30, 2025
AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales increase in Q1.
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
Shares of AbbVie (ABBV) have gained more than 12% in the past week. But now they are overbought and may reverse.
Via Benzinga · April 29, 2025
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.
Via Benzinga · April 29, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR)
will be reporting earnings tomorrow morning. Here’s what to look for.
Via StockStory · April 29, 2025
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.
Via Talk Markets · April 28, 2025
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · April 28, 2025
Analysts raise AbbVie price targets after strong Q1 results, driven by Skyrizi, Rinvoq growth and strategic moves in Parkinson's disease treatments.
Via Benzinga · April 28, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via Chartmill · April 28, 2025
U.S. stock futures are down in early-morning trade on Monday, after ending the previous week on a high note, with back-to-back sessions of strong rallies.
Via Benzinga · April 28, 2025
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
will be reporting results tomorrow morning. Here’s what investors should know.
Via StockStory · April 28, 2025
Biotech company Regeneron (NASDAQ:REGN)
will be reporting earnings tomorrow morning. Here’s what you need to know.
Via StockStory · April 28, 2025
US Markets Rise as Big Tech Shines, Trade Tensions Remain a Concern
Via Chartmill · April 28, 2025
Despite some near-term pressures in aesthetics and legacy products, the overall outlook for 2025 remains positive.
Via Talk Markets · April 27, 2025
Via The Motley Fool · April 26, 2025
Via Benzinga · April 25, 2025